Regeneron Pharmaceuticals, Inc.
REGN
$527.78
-$19.89-3.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.01% | -20.86% | 33.02% | 47.90% | -11.71% |
| Total Depreciation and Amortization | 11.22% | 11.86% | 15.46% | 17.07% | 14.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -108.52% | 351.11% | -155.43% | -1,002.17% | 12.66% |
| Change in Net Operating Assets | -70.58% | -40.72% | 66.77% | -1,017.47% | 82.86% |
| Cash from Operations | -30.90% | 15.89% | 15.88% | -65.38% | 10.60% |
| Capital Expenditure | -71.25% | 20.60% | -37.44% | -59.73% | 24.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -202.63% | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 156.45% | 197.20% | -23.51% | 82.77% | -2,601.22% |
| Cash from Investing | 138.38% | 629.61% | -15.74% | 76.66% | -615.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.12% | -69.80% | -5.17% | 382.47% | 40.58% |
| Repurchase of Common Stock | -64.68% | -64.15% | -26.54% | -29.90% | 21.38% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,412.53% | -154.54% | -55.66% | 22.16% | 114.60% |
| Foreign Exchange rate Adjustments | 220.00% | -450.00% | 500.00% | 25.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 571.88% | -17.38% | -60.29% | 65.56% | -115.81% |